PureTech Publishes Phase 2b IPF Results PureTech published Phase 2b IPF results on Apr 2, 2026 (Investing.com). IPF median survival ~3–5 years; two drugs have been approved since 2014, shaping commercial hurdles.

PureTech Publishes Phase 2b IPF Results: PureTech published Phase 2b IPF results on Apr 2, 2026 (Investing.com). IPF median survival ~3–5 years; two drugs have been approved since 2014, shaping commercial hurdles. 👈 Read full analysis #PureTech #IPF #Phase2b #ClinicalTrials #Pharmaceuticals

Lundbeck preps phase 3 for migraine prevention drug Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.

#Lundbeck #phase3 #migraineprevention #migrainepreventiondrug #bocunebart #antiPACAPantibody #phase2b #PROCEEDtrial #intravenousbocunebart #LuAG09222 #monthlymigrainedays #MMD #PACAP #neuropeptide #pathophysiologyofmigraine #migrainetreatment #PACAPpathway #migrainepreventionmarket
zurl.co/M7FHE

Insmed stock soars on positive Phase 2b study results Investing.com -- Shares of Insmed Incorporated (NASDAQ:INSM) surged 27% following the announcement of positive topline results from its Phase 2b study of Treprostinil Palmitil Inhalation Powder (TPIP) in patients with pulmonary arterial hypertension (PAH). The company reported that the study met its primary and all secondary efficacy endpoints, leading to investor optimism about the drug’s potential. The Bridgewater, New Jersey-based biopharmaceutical company disclosed that the study achieved a statistically significant 35% placebo-adjusted reduction from baseline in pulmonary vascular resistance, the primary endpoint. Secondary endpoints also showed favorable outcomes, including a 35.5-meter placebo-adjusted improvement in six-minute walk distance and a 60% placebo-adjusted reduction from baseline in NT-proBNP concentrations, both of which are indicators of the drug’s effectiveness. Insmed’s announcement also highlighted the tolerability of TPIP, with 75% of patients reaching the highest dose in the study without significant issues. The company plans to engage with the FDA to inform Phase 3 trial design, with studies expected to begin before the end of 2025 for PH-ILD and in early 2026 for PAH. The promising results from the Phase 2b study not only demonstrate TPIP’s potential as a once-daily therapy but also suggest its capability to become a preferred prostanoid treatment for PAH. Insmed’s commitment to advancing this treatment is evident as they prepare for the next stages of clinical trials. The positive reaction in Insmed’s stock price reflects the market’s confidence in the company’s pipeline and its ability to bring new therapies to market. Investors will likely keep a close watch on Insmed as it progresses with its Phase 3 trials and further engages with regulatory authorities. Following the release, competitors Liquidia Technologies (NASDAQ:LQDA) and United Therapeutics (NASDAQ:UTHR) Corporation fell 23.6% and 11.7%, respectively. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Insmed #StockMarket #Investing #Phase2B #Biotech